Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

Phase 2

Completed

Conditions: Type II Diabetes Mellitus
Renal Insufficiency

Interventions: Drug: MEDI0382
Drug: Placebo

First Posted Date: 2018-06-08

Last Posted Date: 2020-04-13

Lead Sponsor: MedImmune LLC

Target Recruit Count: 41

Registration Number: NCT03550378

Locations: 🇬🇧
Research Site, Edinburgh, United Kingdom

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Selected Advanced Solid Tumors

Interventions: Biological: MEDI5752
Drug: Pemetrexed
Biological: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel or Nab-Paclitaxel

First Posted Date: 2018-05-21

Last Posted Date: 2024-06-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 401

Registration Number: NCT03530397

Locations: 🇨🇳
Research Site, Taipei, Taiwan

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

First Posted Date: 2018-04-05

Last Posted Date: 2022-03-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 107

Registration Number: NCT03489525

Locations: 🇪🇸
Research Site, Badalona, Spain

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: MEDI0382
Drug: Dapaglifozin
Drug: Metformin

First Posted Date: 2018-02-23

Last Posted Date: 2020-01-13

Lead Sponsor: MedImmune LLC

Target Recruit Count: 49

Registration Number: NCT03444584

Locations: 🇬🇧
Research Site, Rotherham, United Kingdom

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

Phase 1

Completed

Conditions: Safety
Healthy Subjects

Interventions: Drug: MEDI0382
Drug: Placebo

First Posted Date: 2017-12-28

Last Posted Date: 2019-04-16

Lead Sponsor: MedImmune LLC

Target Recruit Count: 32

Registration Number: NCT03385369

Locations: 🇺🇸
Research Site, Anaheim, California, United States

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Oleclumab
Drug: Osimertinib
Drug: AZD4635

First Posted Date: 2017-12-21

Last Posted Date: 2025-06-10

Lead Sponsor: MedImmune LLC

Target Recruit Count: 43

Registration Number: NCT03381274

Locations: 🇨🇳
Research Site, Taichung, Taiwan

A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: MEDI7219
Drug: Placebo
Drug: Formulation without Active Drug

First Posted Date: 2017-12-05

Last Posted Date: 2020-08-31

Lead Sponsor: MedImmune LLC

Target Recruit Count: 186

Registration Number: NCT03362593

Locations: 🇬🇧
Research Site, Ruddington, United Kingdom

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

Phase 2

Completed

Conditions: Stable Coronary Heart Disease

Interventions: Drug: MEDI5884
Drug: Placebo

First Posted Date: 2017-11-24

Last Posted Date: 2020-03-23

Lead Sponsor: MedImmune LLC

Target Recruit Count: 133

Registration Number: NCT03351738

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: MEDI0382
Drug: Warfarin
Drug: Esmolol

First Posted Date: 2017-11-20

Last Posted Date: 2018-04-25

Lead Sponsor: MedImmune LLC

Target Recruit Count: 22

Registration Number: NCT03347968

Locations: 🇺🇸
Research Site, Daytona Beach, Florida, United States

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: MEDI0382 Formulation 2
Drug: MEDI0382 Formulation 3

First Posted Date: 2017-11-14

Last Posted Date: 2018-02-14

Lead Sponsor: MedImmune LLC

Target Recruit Count: 24

Registration Number: NCT03341013

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy